DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Radiodermititis Market: By Product type (Topical, Oral Medication and Dressings), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy Store, and Online Store) & By Region-Forecast (2016-2021)" report to their offering.
This report identifies the global radiodermititis market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global radiodermititis market.
Geographically Asia-Pacific dominated radiodermititis market driven by best in the developing healthcare infrastructure, increasing awareness, increasing cancer patients and growing spending by the citizens towards healthcare expenditure. Asia-Pacific was followed by Europe and North America as second and third largest market for radiodermititis market.
Asia Pacific is projected to have fastest growth, owing to rapidly increasing healthcare infrastructure, increased spending, government initiatives and increasing awareness amongst population, and growing medical tourism industry in developing nations such as China, and India in this region.
Scope of the Report
Radiodermititis Market, By Product Type:
- Topical
- Oral Medication
- Dressings
-
Others
Radiodermititis Market, By Distribution channel:
- Hospital Pharmacy
- Retail Pharmacy Store
- Online Store
- Others
Some of the major companies' profiles in detail are as follows:
- 3M Health Care
- BMG Pharma
- Molnlycke Health Care
- Smith & Nephew plc
- Derma Sciences, Inc.
- Alliqua Biomedical
- Acelity LP
- Intermed Pharmaceuticals
- Stratpharma AG
- Bayer Healthcare
For more information about this report visit http://www.researchandmarkets.com/research/lc94vg/radiodermititis
